The inhaled anticholinergic agent, aclidinium bromide, reverses cholinergic-induced bronchoconstriction in guinea pigs with a fast onset of action and a long duration of effect
M. Miralpeix, C. Carreño, R. Otal, B. Reyes, C. Carcasona, J. Llenas, H. Ryder, J. Beleta, A. Gavaldà (Barcelona, Spain)
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Miralpeix, C. Carreño, R. Otal, B. Reyes, C. Carcasona, J. Llenas, H. Ryder, J. Beleta, A. Gavaldà (Barcelona, Spain). The inhaled anticholinergic agent, aclidinium bromide, reverses cholinergic-induced bronchoconstriction in guinea pigs with a fast onset of action and a long duration of effect. Eur Respir J 2008; 32: Suppl. 52, 3642
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Compound X – an inhaled β2 agonist with equivalent potency and superior duration of action (DOA)/ therapeutic index (TI) to salmeterol in the anaesthetised dog model of bronchoconstriction Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
The bronchodilator effects of the novel anti-inflammatory compound TPI 1020, alone and in combination with formoterol, in conscious guinea pigs Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009
The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
NVA237 has similar efficacy as tiotropium bromide against methacholine-induced bronchoconstriction and less systemic effect on cardiovascular variables in an anaesthetized rabbit model Source: Eur Respir J 2006; 28: Suppl. 50, 436s Year: 2006
Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011
Glycopyrrolate exerts medium-duration bronchodilator activity in guinea-pig and human airways Source: Eur Respir J 2005; 26: Suppl. 49, 216s Year: 2005
Bronchodilation from formoterol and terbutaline has similar onset of action in asthmatic children Source: Eur Respir J 2002; 20: Suppl. 38, 431s Year: 2002
Effect of aclidinium bromide, a novel long-acting anticholinergic, on salivation, colonic motility and faecal output in different animal models Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008
Assessment of the potency and duration of action of aclidinium bromide in guinea pig isolated trachea in vitro Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007
In vivo, aclidinium bromide has longer duration of action and reduced potential to induce dry mouth, compared with glycopyrrolateSource: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010
Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol Source: Eur Respir J 2001; 17: 368-373 Year: 2001
Rate of onset of action of aclidinium bromide, a novel, long-acting, muscarinic antagonist Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
LAS100977, a novel β2 -agonist, has a longer duration of action and a more favourable therapeutic index than salmeterol in anaesthetised dogs Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
PF-00610355 – an inhaled β2 adrenoceptor agonist with superior potency and duration of action (DoA) to salmeterol in the conscious dog model of bronchoconstriction Source: Annual Congress 2009 - Models of chronic airways disease and therapy Year: 2009
Intermittent administration of salmeterol does not induce tolerance to the bronchoprotective effect in exercise induced bronchoconstriction Source: Eur Respir J 2003; 22: Suppl. 45, 497s Year: 2003
Inhaled montelukast inhibits cysteinyl-leukotriene-induced bronchoconstriction in ovalbumin-sensitized guinea-pigs: the potential as a new asthma medication Source: Annual Congress 2009 - Models of chronic airways disease and therapy Year: 2009
Ipratropium bromide pre-treatment influences recovery after methacholine induced bronchospasm Source: Eur Respir J 2002; 20: Suppl. 38, 505s Year: 2002
Long-acting anticholinergic, aclidinium bromide (AB) significantly attenuates airway inflammation and hyper-responsiveness in an AF -induced murine model of asthma Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009
Influence of the long-acting beta 2-agonist indacaterol on the citric acid-induced cough model in conscious guinea pigs Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
Budesonide prevents cytokine-induced decrease of the relaxant response to formoterol but not to salmeterol in mouse trachea Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009